Drug intelligence / Profile preview

ILV-001

Development stage: Preclinical
Lead developer: Ilonov

Overview

ILV-001 is a drug candidate developed by Ilonov for the treatment of type 1 diabetes mellitus. It is described as mimicking a muscle secretome, suggesting it may act via endocrine pathways relevant to glucose metabolism. The precise mechanism of action has not been defined in public sources. As of the latest updates, ILV-001 is classified as an antihyperglycaemic agent and remains in preclinical development for type 1 diabetes mellitus[1][3].

Other names: ILV 001ILV001ILV-001

Beyond the preview

Go deeper on ILV-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ILV-001.

Explore the full profile